Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine

Seeking Alpha2022-01-12

Pfizer announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Twinkoink
2022-01-13
Twinkoink
Pls go up!!!!!!
MayTan
2022-01-13
MayTan
Great!
Jess261
2022-01-13
Jess261
Okay
Miketee74
2022-01-13
Miketee74
Great!
iams3by
2022-01-13
iams3by
Time to buy more
UTOtrader
2022-01-13
UTOtrader
Buy more Pfizer

Leave a comment

150

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117693983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-12 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117693983","market":"us","top_or_hot":-1,"title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","media":"Seeking Alpha","content":"<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","article_id":"1117693983","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","pubTimestamp":1641989077,"sourceInfo":null,"weMediaInfo":null,"summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞报告新冠肺炎疫苗Prevnar20第三期研究结果呈阳性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9002534661,"gmtCreate":1642037299888,"gmtModify":1676533674737,"author":{"id":"4102144009538240","authorId":"4102144009538240","name":"Twinkoink","avatar":"https://static.itradeup.com/news/28b509cb6921dfb7806f5c832f0b7d3a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls go up!!!!!!","listText":"Pls go up!!!!!!","text":"Pls go up!!!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002534661","repostId":1117693983,"repostType":2,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002539591,"gmtCreate":1642036239251,"gmtModify":1676533674532,"author":{"id":"3573019619191060","authorId":"3573019619191060","name":"MayTan","avatar":"https://static.tigerbbs.com/808e2dbe5d70103ebf181c1496a31644","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1},"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002539591","repostId":1117693983,"repostType":4,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002593522,"gmtCreate":1642035146087,"gmtModify":1676533674292,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002593522","repostId":1117693983,"repostType":4,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002503497,"gmtCreate":1642034133085,"gmtModify":1676533674067,"author":{"id":"3585785590601618","authorId":"3585785590601618","name":"Miketee74","avatar":"https://community-static.tradeup.com/news/09ea58a03e562828bff08f7347bbcdb4","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002503497","repostId":1117693983,"repostType":4,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002210808,"gmtCreate":1642027149507,"gmtModify":1676533672032,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Time to buy more","listText":"Time to buy more","text":"Time to buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002210808","repostId":1117693983,"repostType":2,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9002293509,"gmtCreate":1642024516913,"gmtModify":1676533671526,"author":{"id":"3574547619690492","authorId":"3574547619690492","name":"UTOtrader","avatar":"https://static.tigerbbs.com/82be6befb29ac8516e463638d3f659d5","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Buy more Pfizer","listText":"Buy more Pfizer","text":"Buy more Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002293509","repostId":1117693983,"repostType":4,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":150,"commentSize":16,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117693983"}